TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05122260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-Griffithsin
Description: intranasal spray administered as a single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal spray administered as a single dose
Study: NCT05709067

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 6 Billion CFU per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 CFU per day
Study: NCT04895293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: Sterile solution
Study: NCT05946291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure injury training
Description: Pressure injury training with mulage application on a standardized patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulated Manneqquin training
Description: Pressure injury training with mulage application on a simulated manneqquin
Study: NCT04739618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda Injectable Product
Description: PD-1 inhibitor antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yervoy Injectable Product
Description: Anti-CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-ablative Cryosurgical freezing
Description: To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
Study: NCT06126952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.
Study: NCT05040152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone-based weight loss intervention
Study: NCT06415994

Intervention type: DRUG
Intervention: Buprenorphine or Methadone Treatment
Description: Pregnant mothers must be taking Buprenorphine or Methadone
Study: NCT06126952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Description: 2 sprays per nostril of Placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day
Study: NCT00881998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Total Hip Arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total Hip Arthroplasty
Study: NCT05008575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CAR NK cells
Description: 6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study: NCT06323278

Intervention type: BEHAVIORAL
Intervention: Cognitive training
Description: The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.

Intervention type: BEHAVIORAL
Intervention: Cognitive training
Description: The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
Study: NCT04856774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701；BP102
Description: Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined.
Study: NCT04501614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
Study: NCT06179303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo clinical imaging for tumor assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluoro Furanyl Norprogesterone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given GnRH analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Estradiol
Description: Given PO
Study: NCT06426329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch, as meaningful touch, is included in complementary medicine in the literature. It provides physical, emotional and spiritual relief, improves physiological health, makes the person feel valuable, gives confidence, peace, calmness and increases self-confidence.
Study: NCT04851873

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
Study: NCT05237648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Voice quality education module
Description: The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vocal hygiene module
Description: The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
Study: NCT05675059

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultations with Moffitt Dietician
Description: Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
Study: NCT06415994

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal and Placental MRI
Description: Two MRIs :~* Second Trimester~* Third Trimester

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal and Placental MRI
Description: Two MRIs :~* Second Trimester~* Third Trimester

Intervention type: BEHAVIORAL
Intervention: Child Developmental Assessment
Description: At 1 year of life child will receive a developmental assessment
Study: NCT06415994

Intervention type: BEHAVIORAL
Intervention: Child Developmental Assessment
Description: At 1 year of life child will receive a developmental assessment

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
Study: NCT05675059

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Food Intake Diary with Fitbit Smartphone application
Description: Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Food Intake Diary with Fitbit Smartphone application
Description: Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
Study: NCT05649969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations with Moffitt Dietician
Description: Participants will have an initial consultation with a dietician and then biweekly follow-up visits (in person or virtually) for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Food Intake Diary with Fitbit smartphone application
Description: Participants will keep a daily diary of food intake with a Fitbit smartphone application and wear a Fitbit for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will complete a questionnaire electronically at baseline and again at week 4, 8, 12 and 16.
Study: NCT06001918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nectero EAST System
Description: Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
Study: NCT06361875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5421
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5424
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5424
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5429
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5429
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5429
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza mRNA Vaccine MRT5429
Description: Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Standard Dose Vaccine
Description: Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza High-Dose Vaccine
Description: Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
Study: NCT06584929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ nicotine patch
Description: Two week supply provided to participants on study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Nicotine Lozenges
Description: Two week supply provided to participants on study.
Study: NCT06427707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion of propofol, lidocaine, Magnesium sulfate
Description: intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of ketamine, lidocaine, Magnesium sulfate
Description: Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate
Description: Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
Study: NCT04611529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Description: Diclofenac 1% gel 4gm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical diclofenac
Description: Diclofenac 1% gel 4gm
Study: NCT06175988

Intervention type: OTHER
Intervention: Visceral adiposity
Description: Visceral adiposity assess by the visceral adiposity index
Study: NCT04803201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Given PO
Study: NCT05470023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC Toothpastes or Mouthrinses
Description: OTC Toothpastes or mouthrinses used according to standard of care
Study: NCT05679908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-1900
Description: Patients will spray TNX-1900 once into each nostril.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-1900
Description: Patients will spray TNX-1900 once into each nostril.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Patients will spray placebo nasal spray once into each nostril.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: Patients will spray placebo nasal spray once into each nostril.
Study: NCT05205733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mail-in semen analysis kit
Description: Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
Study: NCT05397756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observer tool
Description: The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
Study: NCT06327451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Liptor is a capsule in the form of 20 mg, once daily.